Journal
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
Volume 8, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fbioe.2020.624096
Keywords
extracellular vesicles; exosomes; musculoskeletal diseases; MSC; iMP; cell-free therapeutics
Funding
- German Society for Orthopedic and Orthopedic Surgery (DGOOC)
- Interdisciplinary Center for Clinical Research (IZKF) at the University of Wuerzburg [D-361]
- European Social Fund
- Ministry of Science, Research and Arts Baden-Wuerttemberg
- Deutsche Forschungsgemeinschaft (DFG) [FOR2407 (JE642/4-2), 277277765, FOR2722 (ZA561/3-1), 407168728]
Ask authors/readers for more resources
Increasing incidence of musculoskeletal diseases with aging population has led to growing interest in extracellular vesicles (EVs) in research. EVs play a crucial role in communication between cells and environment, with mesenchymal stromal cells (MSCs) being a commonly used source for EV generation and potentially influencing their regenerative potential. Implications for therapeutic applications and practical considerations of EV-based therapies are also discussed in the article.
The incidence of musculoskeletal diseases is steadily increasing with aging of the population. In the past years, extracellular vesicles (EVs) have gained attention in musculoskeletal research. EVs have been associated with various musculoskeletal pathologies as well as suggested as treatment option. EVs play a pivotal role in communication between cells and their environment. Thereby, the EV cargo is highly dependent on their cellular origin. In this review, we summarize putative mechanisms by which EVs can contribute to musculoskeletal tissue homeostasis, regeneration and disease, in particular matrix remodeling and mineralization, pro-angiogenic effects and immunomodulatory activities. Mesenchymal stromal cells (MSCs) present the most frequently used cell source for EV generation for musculoskeletal applications, and herein we discuss how the MSC phenotype can influence the cargo and thus the regenerative potential of EVs. Induced pluripotent stem cell-derived mesenchymal progenitor cells (iMPs) may overcome current limitations of MSCs, and iMP-derived EVs are discussed as an alternative strategy. In the last part of the article, we focus on therapeutic applications of EVs and discuss both practical considerations for EV production and the current state of EV-based therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available